Cancer Patients with ACA Policies Swiftly Reach Out-of-Pocket Caps

Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org ASCO Abstract #6504 FOR IMMEDIATE RELEASE on Saturday, June 4, 2016 DURHAM, N.C. – A hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act marketplace.    The findings, reported by researchers at the Duke Cancer Institute at the American Society of Clinical Oncology meeting in Chicago (Abstract #6504), found that cancer patients buying health insurance coverage through the Affordable Care Act marketplace should take into account annual premiums, out-of-pocket maximums, and potential treatment costs – not just one or another of those factors. Even then, the coverage level did not necessarily predict the amount of expected out-of-pocket costs. “When when using all those criteria, the least expensive choice for patients was often the lower tier policies -- typically sold as the “bronze” option -- but not always,” said senior author Yousuf Zafar, M.D., associate professor in the School of Medicine and the Sanford School of Public Policy at Duke University. “Patients might assume that the bronze policy would be the least expensive compared to silver or gold levels, but it’s important to shop carefully, particularly when considering out-of-po...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1+ ALL) has been considerably improved since the beginning of the BCR-ABL1 tyrosine kinase inhibitors (TKI) era 20 years ago. However, the prognosis of patients with a refractory/relapsed (including molecular relapse) disease is still very dismal. New drugs or combination of new drugs may improve outcomes of these patients. For example, ponatinib, a 3rd-generation oral TKI, known to have activity against BCR-ABL1 T315I mutations, has shown some efficacy in this context. Similarly, a recent study has reported very encouraging results of the bispec...
Source: Blood - Category: Hematology Authors: Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III Source Type: research
ConclusionsUsing whole blood degranulation assay and in vitro degranulation and cytotoxicity assays we report that dasatinib effect on NK cell cytotoxicity is dose- and time-dependent. Our results indicate that dasatinib has a dual effect on NK cell degranulation and affects other NK cell functions including cytokine production and migration. Further studies are needed to evaluate the significance of these findings.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II Source Type: research
Conclusion:This survey demonstrates that pts do not consider disease control with life-long oral medication as cure; rather, cure requires the absence of treatment. Overwhelmingly, pts indicated the importance of continuing CML research with an ultimate goal of treatment-free cure. The advent of oral TKIs has been a tremendous success for pts with this disease. Nevertheless, it remains a source of disruption in pts' lives, particularly through side effects and costs. The HJKC3 was initiated with the goal of curing CML.DisclosuresAtallah: Novartis: Consultancy; Jazz: Consultancy; Pfizer: Consultancy; BMS: Consultancy; Abbvi...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases Source Type: research
This report describes a case of osteonecrosis of the jaw developing after a routine dental extraction in a patient being treated with dasatinib, a tyrosine kinase inhibitor, for chronic myelogenous leukemia. As the role of tyrosine kinase inhibitors in cancer treatment expands, patterns of debilitating complications involving the osseous structures of the oral cavity have begun to emerge, and many long-term side effects of this promising therapy remain unknown. To limit the occurrence of known complications, health care providers and patients must be aware of the potential for serious complications of dasatinib, and approp...
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
This report describes a case of osteonecrosis of the jaw that developed following a routine dental extraction in a patient being treated with dasatinib, a tyrosine kinase inhibitor, for chronic myelogenous leukemia. As the role of tyrosine kinase inhibitors in cancer treatment expands, patterns of debilitating complications involving the osseous structures of the oral cavity have begun to emerge, and many long-term side effects of this promising therapy remain unknown. To limit the occurrence of known complications, health care providers and patients must be aware of the potential for serious complications of dasatinib and...
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: Oral Medicine Source Type: research
ConclusionsThis is the first case in literature about activity of dasatinib in combination with a chemotherapy schedule of oral vinorelbine and capecitabine in advanced breast cancer. This treatment showed both good tolerability and great activity with a long progression free survival of 54  months.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
Liposome‑delivered baicalein induction of myeloid leukemia K562 cell death via reactive oxygen species generation. Mol Med Rep. 2018 Jan 08;: Authors: Wang SX, Wen X, Bell C, Appiah S Abstract Baicalein (BL), a potential cancer chemopreventative flavone, has been reported to inhibit cancer cell growth by inducing apoptosis and causing cell cycle arrest in various human cancer cell models. Delivery of BL via nanoliposomes has been shown to improve its oral bioavailability and long‑circulating property in vivo. However, the role of BL in the inhibition of human chronic myeloid leukemia (CML) K56...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In this study we report the design and development of a novel Protein Tyrosine Kinase (PTK) inhibitor on the basis of pharmacophore modelling. Compound 2-(benzo[d]oxazol-2-ylamino)-N-(2-chloro-4-fluorophenyl)-4-methyl-6-(3-nitrophenyl) pyrimidine-5-carboxamide 31 was obtained containing essential pharmacophore structural features. This compound exhibited highest activity against leukaemia cell line (RPMI-8226) at 0.7244 µM, renal cancer cell line (A498) at 0.8511 µM and prostate cancer cell line (PC-3) at 0.7932 µM on the NCI five dose assay test. The PTK assay provides promising activity at IC50 of...
Source: Bioorganic Chemistry - Category: Chemistry Authors: Tags: Bioorg Chem Source Type: research
Conclusions: Findings offered essential guidance for the adaptation and reinforced the utility of the adapted intervention. Implications for Practice: Adapting existing EBIs for new audiences contributes to advancing findings of evidence-based research, ultimately providing nurses and other healthcare providers with important referral options to interventions that may provide useful strategies to improve quality of life and reduce targeted therapy–related fatigue.
Source: Cancer Nursing - Category: Nursing Tags: Articles: Online Only Source Type: research
BACKGROUNDTyrosine kinase inhibitors (TKIs) improve the survival of patients with chronic myeloid leukemia (CML) dramatically; however, nonadherence to TKI therapy may lead to resistance to the therapy. TKIs are very expensive and are covered under Part D insurance for Medicare patients. To the authors' knowledge, the impact of low‐income subsidy status and cost sharing on adherence among this group has not been well studied in the literature. METHODSSurveillance, Epidemiology, and End Results (SEER) registry data linked with Medicare Part D data from the years 2007 through 2012 were used in the current study. The author...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Funding | Gleevec | Health | Health Insurance | Health Management | Insurance | Leukemia | Oral Cancer | Pediatrics | Study